Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Kent Osborne

Showing results (51-60 of 158) with videos related to

Pageof 16
Sort By:
Cancer Research|September 17, 2008
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenograftsChad J Creighton, Suleiman Massarweh, Shixia Huang, et al.
Breast Cancer Research and Treatment|November 4, 2005
Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancerSyed K Mohsin, D Craig Allred, C Kent Osborne, et al.
Breast (Edinburgh, Scotland)|July 9, 2017
De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistanceJamunarani Veeraraghavan, Carmine De Angelis, Jorge S Reis-Filho, et al.
Breast Cancer Research and Treatment|February 21, 2014
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistanceGladys Morrison, Xiaoyong Fu, Martin Shea, et al.
Cancer|December 20, 2002
Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group studySaul E Rivkin, Stephanie J Green, Danika Lew, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2005
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinaseM Carolina Gutierrez, Simone Detre, Stephen Johnston, et al.
Cancer Research|May 17, 2003
Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parametersSuzanne A W Fuqua, Rachel Schiff, Irma Parra, et al.
Breast Cancer Research and Treatment|October 26, 2005
Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapiesMichelle D Martin, Susan G Hilsenbeck, Syed K Mohsin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2009
Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897Dawn L Hershman, Joseph M Unger, William E Barlow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2004
Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancerLori J Pierce, Laura F Hutchins, Stephanie R Green, et al.
Pageof 16

Showing results (51-60 of 158) with videos related to

Sort By:
Pageof 16
Cancer Research|September 17, 2008
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenograftsChad J Creighton, Suleiman Massarweh, Shixia Huang, et al.
Breast Cancer Research and Treatment|November 4, 2005
Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancerSyed K Mohsin, D Craig Allred, C Kent Osborne, et al.
Breast (Edinburgh, Scotland)|July 9, 2017
De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistanceJamunarani Veeraraghavan, Carmine De Angelis, Jorge S Reis-Filho, et al.
Breast Cancer Research and Treatment|February 21, 2014
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistanceGladys Morrison, Xiaoyong Fu, Martin Shea, et al.
Cancer|December 20, 2002
Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group studySaul E Rivkin, Stephanie J Green, Danika Lew, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2005
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinaseM Carolina Gutierrez, Simone Detre, Stephen Johnston, et al.
Cancer Research|May 17, 2003
Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parametersSuzanne A W Fuqua, Rachel Schiff, Irma Parra, et al.
Breast Cancer Research and Treatment|October 26, 2005
Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapiesMichelle D Martin, Susan G Hilsenbeck, Syed K Mohsin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2009
Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897Dawn L Hershman, Joseph M Unger, William E Barlow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2004
Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancerLori J Pierce, Laura F Hutchins, Stephanie R Green, et al.
Pageof 16